| Outcome Measures: |
Primary: Area under the semaglutide plasma concentration - time curve during a dosing interval at steady state (AUC0-24h,sema,SS), nmol\*h/L, From 0 to 24 hours after the last dosing of oral semaglutide 25 mg on visit 8, day 84|Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state (AUC0-24h,sema,SS), nmol\*h/L, From 0 to 24 hours after the last dosing of oral semaglutide 50 mg on visit 10, day 112 | Secondary: Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state (AUC0-24h,sema,SS), nmol\*h/L, From 0 to 24 hours after the last dosing of oral semaglutide 11.2 mg on visit 6, day 56.|Maximum semaglutide plasma concentration at steady state (Cmax,sema,SS), nmol/L, From 0 to 24 hours after the last dosing of oral semaglutide 11.2 mg on visit 6, day 56|Maximum semaglutide plasma concentration at steady state (Cmax,sema,SS), nmol/L, From 0 to 24 hours after the last dosing of oral semaglutide 25 mg on visit 8, day 84|Maximum semaglutide plasma concentration at steady state (Cmax,sema,SS), nmol/L, From 0 to 24 hours after the last dosing of oral semaglutide 50 mg on visit 10, day 112|Time to maximum semaglutide plasma contraction at steady state (tmax,sema,SS), hour, From 0 to 24 hours after the last dosing of oral semaglutide 25 mg on visit 8, day 84|Time to maximum semaglutide plasma contraction at steady state (tmax,sema,SS), hour, From 0 to 24 hours after the last dosing of oral semaglutide 50 mg on visit 10, day 112|Number of treatment-emergent adverse events, Count, From the time of first dosing (visit 2, day 1) until completion of the follow-up visit (visit 11, day 149)|Change in pulse, Beats/minute, From baseline (visit 2, day 1) to end of treatment (visit 10, day 113)|Change in blood pressure, mmHg, From baseline (visit 2, day 1) to end of treatment (visit 10, day 113)
|
